Controlling and Lowering Blood Pressure With The MOBIUSHD™

This is an open-label, multicenter, first-in-man clinical trial to be conducted inside the
United States. Eligible subjects with stage 2 resistant systemic arterial hypertension
currently being treated with a minimum of three (3) anti-hypertensive drugs, who consent to
study participation will be assigned to treatment with the MobiusHD system.

Potential study participants will be consented and then screened at two (2) baseline visits
beginning at least 30 days prior to MobiusHD placement. Qualified patients will undergo
placement of the MobiusHD under angiographic visualization, and will then be followed for 36
months.

Inclusion Criteria:

- Office cuff SBP ≥ 160 mmHg measured per protocol instructions (Appendix IV) following
at least one (1) month of maximally tolerated therapy with at least three (3)
anti-hypertensive medications, of which at least one (1) must be a diuretic. Any
combination medications will be counted per the active ingredient. (For example,
Zestoretic (Lisinopril +HCTZ) equals two (2) anti-hypertensive medications)

Exclusion Criteria:

- Known or clinically suspected baroreflex failure or autonomic neuropathy